Skip to main navigation Skip to search Skip to main content

Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1

  • Sander F. Garrelfs
  • , Yaacov Frishberg
  • , Sally A. Hulton
  • , Michael J. Koren
  • , William D. O’Riordan
  • , Pierre Cochat
  • , Georges Deschênes
  • , Hadas Shasha-Lavsky
  • , Jeffrey M. Saland
  • , William G. van’t Hoff
  • , Daniel G. Fuster
  • , Daniella Magen
  • , Shabbir H. Moochhala
  • , Gesa Schalk
  • , Eva Simkova
  • , Jaap W. Groothoff
  • , David J. Sas
  • , Kristin A. Meliambro
  • , Jiandong Lu
  • , Marianne T. Sweetser
    • Pushkal P. Garg, Akshay K. Vaishnaw, John M. Gansner, Tracy L. McGregor, John C. Lieske
  • University of Amsterdam
  • Shaare Zedek Medical Center
  • Birmingham Women's and Children's NHS Foundation Trust
  • Jacksonville Ctr Clin Res
  • eStudySite
  • Université de Lyon
  • Hôpital Robert Debré AP-HP
  • Western Galilee Medical Center of Nahariya
  • Icahn School of Medicine at Mount Sinai
  • Great Ormond Street Hospital for Children NHS Foundation Trust
  • University of Bern
  • Rambam Health Care Campus Israel
  • Royal Free London NHS Foundation Trust
  • University of Bonn
  • Al Jalila Children's Hospital
  • Mayo Clinic Rochester, MN
  • Alnylam Pharmaceuticals

Research output: Contribution to journal › Article › peer-review

443 Scopus citations

Fingerprint

Dive into the research topics of 'Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Keyphrases